Procalcitonin: A new biomarker for the cardiologist

International Journal of Cardiology

Volumn 223, Issue , 2016, Pages 390-397

  Schuetz, Philipp ^a   Daniels, Lori B ^b   Kulkarni, Prasad ^c   Anker, Stefan D ^d   Mueller, Beat ^a  

^a Medical University Department   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Asclepius Medical Communications LLC   (United States)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Biomarker; Dyspnea; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; CARDIOLOGIST; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DYSPNEA; EMERGENCY WARD; FEVER; FOLLOW UP; HEART ARREST; HUMAN; INDUCED HYPOTHERMIA; INFECTION RISK; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PNEUMONIA; POST CARDIAC ARREST SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RESPIRATORY TRACT INFECTION; RESUSCITATION; REVIEW; SEPSIS; ACUTE DISEASE; BLOOD; CARDIOVASCULAR DISEASES;

ACUTE DISEASE; BIOMARKERS; CALCITONIN; CARDIOLOGISTS; CARDIOVASCULAR DISEASES; HUMANS;

EID: 84982128307     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.08.204     Document Type: Review

References (74)

1. [1] Maisel, A., Mueller, C., Nowak, R., Peacock, W.F., Landsberg, J.W., Ponikowski, P., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J. Am. Coll. Cardiol. 55 (2010), 2062–2076.
2. [2] Karnath, B., Holden, M.D., Hussain, N., Chest pain: differentiating cardiac from noncardiac causes. Hosp. Physician 40 (2004), 24–27 38.
3. [3] Mitsuma, S.F., Mansour, M.K., Dekker, J.P., Kim, J., Rahman, M.Z., Tweed-Kent, A., et al. Promising new assays and technologies for the diagnosis and management of infectious diseases. Clin. Infect. Dis. 56 (2013), 996–1002.
4. [4] Schuetz, P., Aujesky, D., Muller, C., Muller, B., Biomarker-guided personalised emergency medicine for all - hope for another hype?. Swiss Med. Wkly., 145, 2015, w14079.
5. [5] Schuetz, P., Christ-Crain, M., Muller, B., Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections–hope for hype?. Swiss Med. Wkly. 139 (2009), 318–326.
6. [6] Muller, B., Harbarth, S., Stolz, D., Bingisser, R., Mueller, C., Leuppi, J., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect. Dis., 7, 2007, 10.
7. [7] Schuetz, P., Raad, I., Amin, D.N., Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr. Opin. Crit. Care 19 (2013), 453–460.
8. [8] Schuetz, P., Litke, A., Albrich, W.C., Mueller, B., Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr. Opin. Infect. Dis. 26 (2013), 159–167.
9. [9] Muller, B., White, J.C., Nylen, E.S., Snider, R.H., Becker, K.L., Habener, J.F., Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J. Clin. Endocrinol. Metab. 86 (2001), 396–404.
10. [10] Gogos, C.A., Drosou, E., Bassaris, H.P., Skoutelis, A., Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181 (2000), 176–180.
11. [11] Linscheid, P., Seboek, D., Schaer, D.J., Zulewski, H., Keller, U., Muller, B., Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit. Care Med. 32 (2004), 1715–1721.
12. [12] Christ-Crain, M., Muller, B., Procalcitonin in bacterial infections–hype, hope, more or less?. Swiss Med. Wkly. 135 (2005), 451–460.
13. [13] Christ-Crain, M., Muller, B., Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur. Respir. J. 30 (2007), 556–573.
14. [14] Linscheid, P., Seboek, D., Zulewski, H., Keller, U., Muller, B., Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 146 (2005), 2699–2708.
15. [15] Schuetz, P., Mueller, B., Trampuz, A., Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection 35 (2007), 352–355.
16. [16] Muller, F., Christ-Crain, M., Bregenzer, T., Krause, M., Zimmerli, W., Mueller, B., et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 138 (2010), 121–129.
17. [17] van Nieuwkoop, C., Bonten, T.N., van't Wout, J.W., Kuijper, E.J., Groeneveld, G.H., Becker, M.J., et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit. Care, 14, 2010, R206.
18. [18] Schuetz, P., Christ-Crain, M., Zimmerli, W., Mueller, B., Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence, 2010.
19. [19] Schuetz, P., Widmer, I., Chaudri, A., Christ-Crain, M., Zimmerli, W., Mueller, B., Prognostic value of procalcitonin in community-acquired pneumonia. Eur. Respir. J., 2010.
20. [20] Christ-Crain, M., Stolz, D., Bingisser, R., Muller, C., Miedinger, D., Huber, P.R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med. 174 (2006), 84–93.
21. [21] Kruger, S., Ewig, S., Marre, R., Papassotiriou, J., Richter, K., von Baum, H., et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur. Respir. J. 31 (2008), 349–355.
22. [22] Huang, D.T., Weissfeld, L.A., Kellum, J.A., Yealy, D.M., Kong, L., Martino, M., et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann. Emerg. Med. 52 (2008), 48–58 e2.
23. [23] Haeuptle, J., Zaborsky, R., Fiumefreddo, R., Trampuz, A., Steffen, I., Frei, R., et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 28 (2009), 55–60.
24. [24] Jensen, J.U., Heslet, L., Jensen, T.H., Espersen, K., Steffensen, P., Tvede, M., Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit. Care Med. 34 (2006), 2596–2602.
25. [25] Jones, A.E., Fiechtl, J.F., Brown, M.D., Ballew, J.J., Kline, J.A., Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann. Emerg. Med. 50 (2007), 34–41.
26. [26] Schuetz, P., Amin, D.N., Greenwald, J.L., Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 141 (2012), 1063–1073.
27. [27] Schuetz, P., Chiappa, V., Briel, M., Greenwald, J.L., Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch. Intern. Med. 171 (2011), 1322–1331.
28. [28] de Jong, E., van Oers, J.A., Beishuizen, A., Vos, P., Vermeijden, W.J., Haas, L.E., et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect. Dis. 16 (2016), 819–827.
29. [29] Schuetz, P., Briel, M., Mueller, B., Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 309 (2013), 717–718.
30. [30] Schuetz, P., Muller, B., Christ-Crain, M., Stolz, D., Tamm, M., Bouadma, L., et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst. Rev., 9, 2012, CD007498.
31. [31] Schuetz, P., Balk, R., Briel, M., Kutz, A., Christ-Crain, M., Stolz, D., et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin. Chem. Lab. Med. 53 (2015), 583–592.
32. [32] Maisel, A., Neath, S.X., Landsberg, J., Mueller, C., Nowak, R.M., Peacock, W.F., et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur. J. Heart Fail. 14 (2012), 278–286.
33. [33] Schuetz, P., Kutz, A., Grolimund, E., Haubitz, S., Demann, D., Vogeli, A., et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int. J. Cardiol. 175 (2014), 464–472.
34. [34] Tsuyuki, R.T., McKelvie, R.S., Arnold, J.M., Avezum, A. Jr., Barretto, A.C., Carvalho, A.C., et al. Acute precipitants of congestive heart failure exacerbations. Arch. Intern. Med. 161 (2001), 2337–2342.
35. [35] Wuerz, R.C., Meador, S.A., Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann. Emerg. Med. 21 (1992), 669–674.
36. [36] Fonarow, G.C., Abraham, W.T., Albert, N.M., Stough, W.G., Gheorghiade, M., Greenberg, B.H., et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch. Intern. Med. 168 (2008), 847–854.
37. [37] Wang, W., Zhang, X., Ge, N., Liu, J., Yuan, H., Zhang, P., et al. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4698 cases. Crit. Care, 18, 2014, R4.
38. [38] Morgenthaler, N.G., Struck, J., Fischer-Schulz, C., Bergmann, A., Sensitive immunoluminometric assay for the detection of procalcitonin. Clin. Chem. 48 (2002), 788–790.
39. [39] Schuetz, P., Christ-Crain, M., Thomann, R., Falconnier, C., Wolbers, M., Widmer, I., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302 (2009), 1059–1066.
40. [40] Alba, G.A., Truong, Q.A., Gaggin, H.K., Gandhi, P.U., De Berardinis, B., Magrini, L., et al. Diagnostic and prognostic utility of procalcitonin in patients presenting to the emergency department with dyspnea. Am. J. Med. 129 (2016), 96–104 e7.
41. [41] Wartenberg, K.E., Stoll, A., Funk, A., Meyer, A., Schmidt, J.M., Berrouschot, J., Infection after acute ischemic stroke: risk factors, biomarkers, and outcome. Stroke Res. Treat., 2011, 2011, 830614.
42. [42] van de Beek, D., Wijdicks, E.F., Vermeij, F.H., de Haan, R.J., Prins, J.M., Spanjaard, L., et al. Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis. Arch. Neurol. 66 (2009), 1076–1081.
43. [43] Ulm, L., Ohlraun, S., Harms, H., Hoffmann, S., Klehmet, J., Ebmeyer, S., et al. STRoke Adverse outcome is associated WIth NoSocomial Infections (STRAWINSKI): procalcitonin ultrasensitive-guided antibacterial therapy in severe ischaemic stroke patients - rationale and protocol for a randomized controlled trial. Int. J. Stroke, 2012.
44. [44] Hug, A., Murle, B., Dalpke, A., Zorn, M., Liesz, A., Veltkamp, R., Usefulness of serum procalcitonin levels for the early diagnosis of stroke-associated respiratory tract infections. Neurocrit. Care. 14 (2011), 416–422.
45. [45] Wang, C., Gao, L., Zhang, Z.G., Li, Y.Q., Yang, Y.L., Chang, T., et al. Procalcitonin is a stronger predictor of long-term functional outcome and mortality than high-sensitivity C-reactive protein in patients with ischemic stroke. Mol. Neurobiol., 2015.
46. [46] Pierce, D., Calkins, B.C., Thornton, K., Infectious endocarditis: diagnosis and treatment. Am. Fam. Physician 85 (2012), 981–986.
47. [47] Rast, A.C., Kutz, A., Felder, S., Faessler, L., Steiner, D., Laukemann, S., et al. Procalcitonin improves the Glasgow Prognostic Score for outcome prediction in emergency patients with cancer: a cohort study. Dis. Markers, 2015, 2015, 795801.
48. [48] Rast, A.C., Knobel, D., Faessler, L., Kutz, A., Felder, S., Laukemann, S., et al. Use of procalcitonin, C-reactive protein and white blood cell count to distinguish between lower limb erysipelas and deep vein thrombosis in the emergency department: a prospective observational study. J. Dermatol. 42 (2015), 778–785.
49. [49] Laukemann, S., Kasper, N., Kulkarni, P., Steiner, D., Rast, A.C., Kutz, A., et al. Can we reduce negative blood cultures with clinical scores and blood markers? Results from an observational cohort study. Medicine (Baltimore), 94, 2015, e2264.
50. [50] Mueller, C., Huber, R., Laifer, G., Mueller, B., Buerkle, G., Perruchoud, A.P., Procalcitonin and the early diagnosis of infective endocarditis. Circulation 109 (2004), 1707–1710.
51. [51] Yu, C.W., Juan, L.I., Hsu, S.C., Chen, C.K., Wu, C.W., Lee, C.C., et al. Role of procalcitonin in the diagnosis of infective endocarditis: a meta-analysis. Am. J. Emerg. Med. 31 (2013), 935–941.
52. [52] Knudsen, J.B., Fuursted, K., Petersen, E., Wierup, P., Molgaard, H., Poulsen, S.H., et al. Procalcitonin in 759 patients clinically suspected of infective endocarditis. Am. J. Med. 123 (2010), 1121–1127.
53. [53] Blake, G.J., Ridker, P.M., C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am. Coll. Cardiol. 41 (2003), 37S–42S.
54. [54] Remskar, M., Horvat, M., Hojker, S., Noc, M., Procalcitonin in patients with acute myocardial infarction. Wien. Klin. Wochenschr. 114 (2002), 205–210.
55. [55] Sinning, C.R., Sinning, J.M., Schulz, A., Schnabel, R.B., Lubos, E., Wild, P.S., et al. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ. J. 75 (2011), 1184–1191.
56. [56] Engel, H., Ben Hamouda, N., Portmann, K., Delodder, F., Suys, T., Feihl, F., et al. Serum procalcitonin as a marker of post-cardiac arrest syndrome and long-term neurological recovery, but not of early-onset infections, in comatose post-anoxic patients treated with therapeutic hypothermia. Resuscitation 84 (2013), 776–781.
57. [57] Bro-Jeppesen, J., Kjaergaard, J., Wanscher, M., Nielsen, N., Friberg, H., Bjerre, M., et al. The inflammatory response after out-of-hospital cardiac arrest is not modified by targeted temperature management at 33 degrees C or 36 degrees C. Resuscitation, 2014.
58. [58] Stammet, P., Devaux, Y., Azuaje, F., Werer, C., Lorang, C., Gilson, G., et al. Assessment of procalcitonin to predict outcome in hypothermia-treated patients after cardiac arrest. Crit. Care Res. Pract., 2011, 2011, 631062.
59. [59] Varon, J., Polderman, K., Procalcitonin for prognostication after cardiac arrest: another piece of the puzzle?. Resuscitation 84 (2013), 718–719.
60. [60] Schuetz, P., Albrich, W., Mueller, B., Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med., 9, 2011, 107.
61. [61] Schuetz, P., Briel, M., Christ-Crain, M., Stolz, D., Bouadma, L., Wolff, M., et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin. Infect. Dis. 55 (2012), 651–662.
62. [62] Fries, M., Kunz, D., Gressner, A.M., Rossaint, R., Kuhlen, R., Procalcitonin serum levels after out-of-hospital cardiac arrest. Resuscitation 59 (2003), 105–109.
63. [63] Adib-Conquy, M., Monchi, M., Goulenok, C., Laurent, I., Thuong, M., Cavaillon, J.M., et al. Increased plasma levels of soluble triggering receptor expressed on myeloid cells 1 and procalcitonin after cardiac surgery and cardiac arrest without infection. Shock 28 (2007), 406–410.
64. [64] Los Arcos, M., Rey, C., Concha, A., Medina, A., Prieto, B., Acute-phase reactants after paediatric cardiac arrest. Procalcitonin as marker of immediate outcome. BMC Pediatr., 8, 2008, 18.
65. [65] Fries, M., Stoppe, C., Brucken, D., Rossaint, R., Kuhlen, R., Influence of mild therapeutic hypothermia on the inflammatory response after successful resuscitation from cardiac arrest. J. Crit. Care 24 (2009), 453–457.
66. [66] Hayashida, H., Kaneko, T., Kasaoka, S., Oshima, C., Miyauchi, T., Fujita, M., et al. Comparison of the predictability of neurological outcome by serum procalcitonin and glial fibrillary acidic protein in postcardiac-arrest patients. Neurocrit. Care. 12 (2010), 252–257.
67. [67] Schuetz, P., Affolter, B., Hunziker, S., Winterhalder, C., Fischer, M., Balestra, G.M., et al. Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur. J. Clin. Investig. 40 (2010), 376–381.
68. [68] Annborn, M., Dankiewicz, J., Erlinge, D., Hertel, S., Rundgren, M., Smith, J.G., et al. Procalcitonin after cardiac arrest - an indicator of severity of illness, ischemia–reperfusion injury and outcome. Resuscitation 84 (2013), 782–787.
69. [69] Hottenrott, S., Schummer, W., Value of procalcitonin as an outcome-parameter after cardiac arrest. Resuscitation 84 (2013), e25–e26.
70. [70] Schuetz, P., Christ-Crain, M., Albrich, W., Zimmerli, W., Mueller, B., Pro, H.S.G., Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence 1 (2010), 88–92.
71. [71] Loncar, G., Tscholl, V., Tahirovic, E., Sekularac, N., Marx, A., Obradovic, D., et al. Should procalcitonin be measured routinely in acute decompensated heart failure?. Biomark. Med 9 (2015), 651–659.
72. [72] Mollar, A., Villanueva, M.P., Montalvo, E., Palau, P., Santas, E., Carratala, A., et al. Procalcitonin predicts long-term mortality in patients with acute heart failure. Eur. J. Heart Fail., 16, 2014.
73. [73] Villanueva, M.P., Mollar, A., Palau, P., Carratala, A., Nunez, E., Santas, E., et al. Procalcitonin and long-term prognosis after an admission for acute heart failure. Eur. J. Intern. Med. 26 (2015), 42–48.
74. [74] Cinar, O., Cevik, E., Acar, A., Kaya, C., Ardic, S., Comert, B., et al. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients. Am. J. Emerg. Med. 30 (2012), 1915–1920.